Bevacizumab biosimilar (Prestige BioPharma/Hanwha Biologics)

贝伐珠单抗生物类似药 (Prestige BioPharma/Hanwha Biologics)

Report date: 2022/07/04 19:38:02

Base Information

Drug NameBevacizumab biosimilar (Prestige BioPharma/Hanwha Biologics)

Drug Alias Name贝伐珠单抗生物仿制药 (Prestige BioPharma/Hanwha Biologics)贝伐人源化单抗生物仿制药 (Prestige BioPharma/Hanwha Biologics)贝伐赛珠单抗生物仿制药(Prestige BioPharma/Hanwha Biologics)贝伐单抗生物仿制药 (Prestige BioPharma/Hanwha Biologics)HD-204

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBulgariaUnited StatesUkraine +[19]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesHanwha Biologics

China Registration ClassN/A

Develop Information

Active CompaniesPharmapark National Cancer Institute Intas Pharmaceuticals Ltd +[4]

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungLung Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeL01XC07